With $750 million in facility-specific investment and 250 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Roche Group (Genentech)
- Industry
- Pharmaceuticals
- Location
- Hillsboro, Oregon
- Investment
- $750.0M
- Permanent jobs announced
- 250
- Status
- Planning
- Announced
- Aug 20, 2026
- Expected opening
- 2031
- Added to tracker
- Sep 1, 2026
Official references
- Roche and Genentech's August 20, 2026 Hillsboro device fill-finish manufacturing announcement https://www.roche.com/media/releases/med-cor-2026-08-20
- Genentech's August 2026 Hillsboro manufacturing-expansion announcement https://www.gene.com/media/press-releases/15123/2026-08-20/genentech-announces-manufacturing-expans
- Genentech Hillsboro Technical Operations campus address and manufacturing profile https://www.gene.com/contact-us/visit-us/hillsboro